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We established previously that IGFBP-3 could exert positive or negative effects on cell
function depending upon the extracellular matrix composition and by interacting with inte-
grin signaling.To elicit its pro-apoptotic effects IGFBP-3 bound to caveolin-1 and the beta 1
integrin receptor and increased their association culminating in MAPK activation. Disrup-
tion of these complexes or blocking the beta 1 integrin receptor reversed these intrinsic
actions of IGFBP-3. In this studywe have examined the signaling pathway between integrin
receptor binding and MAPK activation that mediates the intrinsic, pro-apoptotic actions of
IGFBP-3. We found on inhibiting protein kinase A (PKA), Rho associated kinase (ROCK),
and ceramide, the accentuating effects of IGFBP-3 on apoptotic triggers were reversed,
such that IGFBP-3 then conferred cell survival.We established that IGFBP-3 activated Rho,
the upstream regulator of ROCK and that beta1 integrin and PKA were upstream of Rho
activation, whereas the involvement of ceramide was downstream. The beta 1 integrin,
PKA, Rho, and ceramide were all upstream of MAPK activation. These data highlight key
components involved in the pro-apoptotic effects of IGFBP-3 and that inhibiting them leads
to a reversal in the action of IGFBP-3.
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INTRODUCTION
The IGFs are present in the body almost entirely in association
with speciﬁc binding proteins of which there are a family of six
closely related but distinct proteins (IGFBPs 1–6): IGFBP-3 being
the major IGF binding protein in human serum. IGFBPs-3 and -5
are the most structurally similar IGFBPs and share a number of
common features (Jones and Clemmons, 1995; Perks and Holly,
2003). In addition to either enhancing or inhibiting the actions of
IGFs, it is now clear that IGFBPs can also have IGF-independent
effects on cell function that can also be both positive and negative.
IGFBP-3 is known to mediate the growth inhibitory effects of a
number of different agents including vitamin D3 and TGF-beta
(Perks and Holly, 2003) and inhibits cell growth in human breast
cancer cells (Oh et al., 1995). Conversely it has also been reported
that IGFBP-3 can promote growth in non-malignant mammary
epithelial cells (McCaig et al., 2002a), in colon cancer cells (Kansra
et al., 2000), LnCaP prostate cancer cells (Martin and Pattison,
2000), and in human airway smooth muscle cells (Cohen et al.,
2000). The intrinsic ability of IGFBP-3 to exert differential effects
on cell growth is also reﬂected in its ability to modulate apoptosis
in an IGF-independent manner. There have been many reports
that IGFBP-3 can accentuate apoptosis of different cells including
prostate (Rajah et al., 1997), breast (Gill et al., 1997), colorectal
(Williams et al., 2000), and esophageal (Hollowood et al., 2000)
epithelial cells and induce cell death alone in prostate cancer cells
(Rajah et al., 1997) but IGFBP-3 can also inhibit apoptosis of non-
malignant mammary epithelial cells (McCaig et al., 2002a) and of
HUVEC cells (Granata et al., 2004).
In an attempt to determine how IGFBP-3 exerts its intrinsic
actions, there was a report of an IGFBP-3 cell surface binding
site (Oh et al., 1993) and this has recently been suggested to be
a novel receptor for IGFBP-3 that mediates only pro-apoptotic
effects (Ingermann et al., 2010). It was also reported that IGFBP-3
associated with the TGF-beta V receptor (Leal et al., 1997). Sig-
nal transduction initiated by IGFBP-3 in T47D breast cancer cells,
was shown to require TGF-beta receptors and its signaling inter-
mediates, Smad-2 and -3. IGFBP-3 possesses a nuclear localization
sequence (Schedlich et al., 1998) which may allow it to enter the
nucleus and in vitro studies have shown that it binds to the nuclear
retinoid X receptor (RXR; Schedlich et al., 1998; Liu et al., 2000).
Translocation of IGFBP-3 to the nucleus and subsequent effects
on gene transcription may be a possible mechanism by which
IGFBP-3 could exert some IGF-independent actions,but could not
however explain the very rapid cellular responses such as IGFBP-
3 modulating the phosphorylation status of signaling molecules
such as MAPK (Martin et al., 2003; Burrows et al., 2006) and
SMAD-2 and -3 (Fanayan et al., 2000) or the very rapid effects on
cell adhesion (McCaig et al., 2002b; Martin and Jambazov, 2006).
Cellular responses such as growth, survival, and migration are
regulated by soluble growth factors as well as interaction with
the extracellular matrix. Integrins are a family of heterodimeric
transmembrane receptors, which serve as a link between the extra-
cellular matrix and the intracellular signaling network (Berman
et al., 2003). There is evidence implicating the extracellular matrix
and integrin signaling in the intrinsic actions of the IGFBPs. Both
IGFBP-1 and -2 contain the classical integrin recognition sequence
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RGD and their cell surface binding has been shown to involve the
α5β1 integrin, which results in both FAK and MAPK deactiva-
tion in Hs578T breast cancer and A67 sarcoma cells culminating
in apoptosis (Jones et al., 1993; Perks et al., 1999b; Schutt et al.,
2004).
Although IGFBP-3 does not contain an RGD sequence there
is strong evidence to support the involvement of the extracellu-
lar matrix and integrins in its intrinsic actions (Perks and Holly,
2003). We have shown previously that the extracellular matrix
modulates the IGF-independent actions of IGFBP-3. In breast
tumors, disruption of the well-deﬁned, normal ductal tissue archi-
tecture results in reduced exposure of epithelial cells to laminin
and collagen but increased exposure to ﬁbronectin in the stroma.
Increased expression of ﬁbronectin in breast cancers is associ-
ated with poor prognosis and metastasis (Oda et al., 1992). We
found that on laminin and collagen, IGFBP-3 enhances triggers
of apoptosis and reduces attachment of Hs578T cells, but when
plated onto ﬁbronectin these effects of IGFBP-3 were reversed and
IGFBP-3 then promoted adhesion and acted as a survival factor
(McCaig et al., 2002b).We have also recently reported that IGFBP-
3 can inhibit EGF-induced growth of breast cancer cells when
grown on plastic or laminin but promotes EGF-induced prolifera-
tionwhen cultured on ﬁbronectin (McIntosh et al., 2010). Integrin
receptors congregate within cholesterol-stabilized microdomains
within the plasma membrane that form platforms for the clus-
tering of cell signaling components (Brown, 2000) and caveolin 1
is a recognized marker of such microdomains. More recently we
have shown that IGFBP-3 can bind caveolin-1 and the β1 integrin
sub-unit, increase their association and the recruitment of a key
integrin signaling molecule, focal adhesion kinase (Burrows et al.,
2006). Furthermore, we determined that the critical determinant
of whether IGFBP-3 had positive or negative effects on cell func-
tion was dependent on the status of such cholesterol-stabilized
integrin receptor complexes (Burrows et al., 2006). These data
showed that the intrinsic actions of IGFBP-3 depend not only on
cell type but also importantly on cell context and this underlies
whether IGFBP-3 will exert either a positive or negative effect on
cell function. In this study we have tried to delineate further the
pro-apoptotic signaling pathway of IGFBP-3, which may provide
a better understanding of therapeutic responses to drugs that act
in concert with IGFBP-3 and whose actions change with tumor
progression.
MATERIALS AND METHODS
MATERIALS
Recombinant, human, non-glycosylated IGFBP-3 (ngIGFBP-3)
was a kind gift from Dr. C. Maack, Celtrix, CA, USA. Recombi-
nant, human, non-glycosylated IGFBP-5 (ngIGFBP-5) was bought
from GroPep, Adelaide, SA, Australia. Serine phosphorylation
domain peptide (SPD) is a 15 amino acid peptide sequence span-
ning the two mid-region serines of IGFBP-3 and mimics all
the intrinsic actions of full-length IGFBP-3 (Hollowood et al.,
2002). It was synthesized at the micro-chemical facility of the
Babraham Institute (Cambridge, UK). The ceramide antibody
was purchased from Alexis Corporation, UK. A negative con-
trol mouse IgM was bought from Dako, Cambridgeshire, UK.
The PKA inhibitor, KT5720 was purchased from Tocris, Bristol,
UK. The Rho kinase inhibitor ROCK, Y-27632, and C2-ceramide
were purchased from Merck, Nottingham, UK. The anti-ERK-
2 antibody was bought from Santa Cruz, CA, USA. The anti-
phospho-MAP kinase antibody was purchased from Promega,
Southampton, UK. The anti-Rho antibody and Rhotekin Rho
binding domain bound to glutathione–agarose were purchased
from Upstate Biotechnology, NY, USA. The anti-beta 1 integrin
blocking antibody was bought from Millipore, Watford, Hert-
fordshire. All other chemicals including antimycin A, an inhibitor
of ceramide synthase, fumonisin B1, an inhibitor of sphingosine
kinase,N,N -dimethylsphingosine (DMS), anti-alpha-tubulin pri-
mary antibody, and TRITC phalloidin stain were bought from
Sigma, Dorset, UK. Tissue culture plastics were obtained from
Greiner Labortechnik Ltd., Tyne and Wear, UK. The BCA protein
assay reagent kit was purchased from Pierce, Illinois, USA.
CELL CULTURES
Human breast cancer cells, Hs578T were purchased from ECACC
(Porton Down, Wiltshire, UK) and grown in a humidiﬁed 5%
carbon dioxide atmosphere at 37˚C. The cells were cultured
in Dulbecco’s modiﬁed Eagles Medium (DMEM, BioWhittaker,
Verviers, Belgium) supplemented with 10% fetal bovine serum
(FBS, Gibco, Paisley, UK), penicillin (50 IU/ml; Britannia Phar-
maceuticals, Redhill, UK), streptomycin (50μg/ml; Celltech Phar-
maceuticals, Slough,UK), and l-glutamine (2mM; Sigma,Dorset,
UK) – growthmedia (GM). For all cell lines experiments were per-
formed in phenol red-and serum-free DMEM and Hams Nutri-
ent Mix F12 with sodium bicarbonate (0.12%; Sigma, Dorset,
UK), bovine serum albumin (BSA) (0.2mg/ml; Sigma, Dorset,
UK), transferrin (0.01mg/ml; Sigma, Dorset, UK) and supple-
mented with penicillin (50 IU/ml), streptomycin (50μg/ml), and
l-glutamine (2mM) – SFM.
TRYPAN BLUE DYE EXCLUSION
Aliquots of cell suspension were loaded onto a haemocytometer
(1:1) with Trypan blue dye.Viable cells exclude the dye. Both living
and dead cells were counted from which the percentage of dead
cells was calculated.
DOSING PROTOCOL FOR APOPTOSIS ASSAY
Hs578T cells were seeded at 0.1× 106 cells/well in six-well plates
in GM and then switched to SFM for 24 h prior to pre-dosing with
SPD (10 ng/ml), IGFBP-3 or IGFBP-5 (each at 100 ng/ml) with or
without either fumonisin B1 (1μM), DMS (0.5μM), a ceramide
antibody (1μg/ml), ROCK (5μM), or a pre-dose for 30min with
KT5720 (0.5μM). The cells were then re-dosed with IGFBP-3 or
IGFBP-5 (each at 100 ng/ml) for a further 24 h in the presence or
absence of an apoptotic dose of either antimycinA orC2-ceramide
(doses chosen to give approximately 40–60%cell death)with either
of the inhibitors listed above. We have shown previously that the
amount of apoptosis as quantiﬁed by ﬂow cytometry is directly
comparable to the amount of cell death measured by Trypan blue
cell counts in these models of cell death (Gill et al., 1997; Perks
et al., 1999a).
PHOTOMICROGRAPHS
To assess changes in the levels of apoptosis in the presence of
apoptotic triggers and morphological alteration in the presence
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of Y-27632 (1, 2, and 5μM), Hs578T cells were viewed under
phase contrast and photomicrographs were captured (magniﬁca-
tion×100) using JVC TK-1281 color video camera on anAxiovert
100 microscope (Zeiss) coupled to a time-lapse video recorder
using Adobe Premiere 4.1.
DETERMINATION OF CHANGES IN ACTIN STRESS FIBERS AND
MICROTUBULE ORGANIZATION INDUCED BY THE RHO KINASE
INHIBITOR
Hs578T cells were seeded at 0.1× 106 cells per coverslip in GM
for 24 h before being placed into SFM for a further 24 h. As the
effects of Y-27632 were most marked between 2 and 6 h, Hs578T
cells were treated with or without Y-27632 (5μM) for 4 h. Fol-
lowing treatment cells were washed with PBS (×2), then ﬁxed in a
4%paraformaldehyde solution for 10min and then permeabilized
with 0.5% triton X-100 for 10min. The coverslips were blocked in
3% goat serum for 30min and incubated with 250μl (1:500) anti-
alpha-tubulin primary antibody in 3% goat serum for 40min. The
coverslips were then rinsed in PBS (×3). Slides were then stained
with 250μl (1:500) TRITC phalloidin in goat serum in conjunc-
tion with incubation of the secondary antibody for tubulin [alexa
ﬂour 488; 250μl (1:250)] in 3% goat serum for 40min. The cov-
erslips were washed in PBS (×3) before being removed from the
plate and air dried for 10min prior to mounting on slides using
Vectasheild and DAPI (Vector Labs Inc, Peterborough, UK). Pho-
tomicrographs were taken using an Olympus BX40 ﬂuorescent
microscope under oil immersion at a magniﬁcation of ×40.
WESTERN IMMUNOBLOTTING
Hs578T cells (0.3× 106) were grown to 80% conﬂuency in T25
ﬂasks and thenwashed twicewith phosphate buffered saline (PBS).
The GM was replaced with SFM for 24 h. The cells were then
treated with ngIGFBP-3 for 30min after a 30 min pre-incubation
with fumonisin B1 (1μM), and then lysed on ice for 10min
(1ml; 10mM Tris HCl, 5mM EDTA, 50mM NaCl, 30mM Na
pyrophosphate, 50mM sodium ﬂuoride, 100μM sodium ortho-
vanadate, 1% Triton and protease and inhibitor cocktails: 1:100).
Lysates were then centrifuged at 14,000 g for 15min at 4˚C. The
protein content of each sample was determined using a BCA
Protein Assay Reagent Kit and equivalent volumes of protein
used. Non-speciﬁc binding sites on the nitro-cellulosemembranes
were blocked overnight with 3% BSA in tris-buffered saline; 2%
TWEEN (TBST) for probing with anti-p-MAPK (1:5000) and 5%
milk in tris-buffered saline; 2% TWEEN (TBST) for probing with
anti-ERK-2 (1:1000). Following the removal of excess unbound
antibody, an anti-rabbit antibody (1:10,000 for p-MAPK), an anti-
goat (1:5000 for ERK-2) conjugated to peroxidase was added for
1 h. Chemiluminescence was detected using the ChemiDoc-IT
Imaging System (UVP) (Biorad, Hertfordshire, UK) and analyzed
using Vision WorksTH ls Analysis Software (UVP Inc., Upland,
CA, USA).
RHO ACTIVATION ASSAYS
Activation assays were performed as described previously (Ren
and Schwartz, 2000; Pellegrin and Mellor, 2008). In brief, Hs578T
were seeded at 0.3× 106 per T25 culture ﬂasks for 24 h after
which the GM was replaced with SFM for 24 h. Cells were
treated with either IGFBP-3 (100 ng/ml) with or without a 30-min
pre-dose with fumonisin B1 (1μM), an anti-beta 1 integrin
antibody (200 ng/ml) or KT5720 (0.5μM), or with sphingosine-
1-phosphate (S1P, 1μM), ranging from 1 to 5min used as
a positive control. Following treatment, the supernatant was
removed and the cells were then washed twice with Tris-buffered
saline (TBS, 50mM Tris base, 140mM NaCl; pH7.6) prior to
cell lysis (50mM Tris HCl pH 7.2, 1% triton X-100, 0.1% SDS,
500mMNaCl, 10mMMgCl2, protease, and phosphatase inhibitor
cocktails, 1:100). Samples were then centrifuged at 14,000 g at
4˚C for 10min. Of the cell lysates, equal volumes were incu-
bated with 20–30μg GST-TRBD beads and rotated at 4˚C for
45min and equal volumes were also removed for assessment
of total Rho as a loading control. The samples were washed
four times with 600μl of tris buffer (TB, 50mM Tris HCl
pH 7.2, 1% triton X-100, 150mM NaCl, 10mM MgCl2 pro-
tease and phosphatase inhibitor cocktails, 1:100) centrifuged at
5000 rpm for 20 s at 4˚C and the supernatant removed. The
samples were eluted with 50μl of Laemmli sample buffer con-
taining 40mM DTT and boiled for 10min. Samples were spun
at 5000 rpm for 20 s and the supernatant was then loaded onto
the gel and SDS-PAGE and Western blotting performed. Non-
speciﬁc binding sites on the nylon membranes were blocked
with 5% milk in tris-buffered saline; 2% TWEEN (TBST) and
incubated with anti-Rho antibody (1:1000) overnight with rota-
tion. Following the removal of excess unbound primary anti-
body, blots were incubated with an anti-rabbit antibody (1:2000)
conjugated to peroxidase for 1 h and processed as described
above.
PROTOCOL FOR ASSESSING CELL SURFACE CERAMIDE USING FLOW
CYTOMETRY
Hs578T cells were pre-dosed with IGFBP-3 as described above,
and then dosed with the apoptotic trigger. Attached cells were
then washed in 0.2% BSA-containing PBS, trypsinized, and then
re-suspended in 0.2% BSA-containing PBS in the presence of
10% FCS. Cells were spun down and re-suspended in a 0.2%
BSA-containing PBS solution of a ceramide antibody or a con-
trol IgM (10μg/ml). The cells were incubated on ice for 30min,
spun down and washed in 0.2% BSA-containing PBS. Cells were
then re-suspended in a 0.2% BSA-containing PBS solution of a
FITC-labeled anti-mouse IgMantibody (7.8μg/ml), incubated for
30min on ice, spun down,washed, and then re-suspended in 0.2%
BSA-containing PBS. Cell surface ceramide was assessed using a
FACS Calibur ﬂow cytometer (BectonDickinson). Analysis was by
Cell Quest software package (Becton Dickinson).
STATISTICAL ANALYSIS
The data were analyzed with using SPSS 12.0.1 for windows soft-
ware using ANOVA followed by least signiﬁcant difference (LSD)
post hoc test. A statistically signiﬁcant difference was considered to
be present at p< 0.05.
RESULTS
PKA INHIBITION REVERSES THE INTRINSIC PRO-APOPTOTIC EFFECTS
OF IGFBP-3
IGFBP-3 binds to caveolin-1 (Burrows et al., 2006) binding
speciﬁcally to its scaffolding domain (CSD) (Lee et al., 2004;
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Singh et al., 2004). One of the main signaling molecules which
binds to the CSD and is inactivated through binding is protein
kinase A (Levin et al., 2007). We investigated if PKA was involved
in the intrinsic effects of IGFBP-3. Figure 1A indicates that in
Hs578T breast cancer cells, the accentuating effects of SPD on
C2-induced apoptosis (p< 0.05) was reversed in the presence of a
PKA inhibitor, KT5720, such that SPD then conferred cell sur-
vival (p< 0.05). In the presence of KT5720 the survival effect
of IGFBP-5 against C2 (p< 0.05) was unaffected (Figure 1B).
Preliminary data also showed that the apoptotic response to
C2 was enhanced in the presence of an activator of PKA,
8-Bromo-cAMP (data not shown) consistent with activation of
PKA being involved in the accentuation of C2-induced apoptosis
by IGFBP-3.
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FIGURE 1 | Hs578T cells were seeded in six-well plates at 0.1× 106 cells
in GM followed by 24h in SFM prior to pre-dosing (A) with SPD
(10ng/ml) or (B) IGFBP-5±KT5720 (1μM).The cells were then re-dosed
with IGFBP-3 or IGFBP-5 (each at 100 ng/ml) for a further 24 h in the
presence or absence of an apoptotic dose of C2-ceramide. The graphs
represent changes in cell death and show the mean±SEM of three
experiments each repeated in triplicate.
RHO KINASE INHIBITION REVERSES THE INTRINSIC PRO-APOPTOTIC
EFFECTS OF IGFBP-3
One of the major downstream targets of PKA is Rho (Leve et al.,
2008) and the assembly of integrin adhesion complexes requires
both RhoGTPases and the extracellularmatrix (Hotchin andHall,
1995). ROCK is a serine/threonine kinase and a key target for Rho
signaling, which induces actin bundling and contraction through
increasing myosin light chain (MLC) phosphorylation (Bishop
and Hall, 2000).
Figure 2A shows the morphology of the Hs578T cells in the
presence of the Rho kinase inhibitor (1, 2, and 5μM) at 4 h.
Despite the more rounded phenotype and increased formation of
long cell processes (lamellipodia/ﬁlopodia), there was no induc-
tion of cell death above basal levels over 24 or 48 h. With the use
of the actin stain phalloidin, we show in Figure 2B that inhibition
of Rho kinase (5μM) resulted in a loss of organized actin con-
taining stress ﬁbers. Using antibodies against α-tubulin we also
observed the loss of the microtubule mesh network as well as
longitudinally orientated tubulin within the protruding cellular
processes.
Figure 2C shows that the accentuating effect of IGFBP-3 on
C2-induced apoptosis (p< 0.001) was reversed in the presence
of the Rho kinase inhibitor, such that IGFBP-3 then conferred
cell survival (p< 0.01). In the presence of Y-27632 IGFBP-5 was
still able to signiﬁcantly decrease C2-ceramide-induced cell death
(p< 0.05) (Figure 2D).
IGFBP-3 ACTIVATES RHO
With Hs578T cells we found that IGFBP-3 rapidly increased
Rho activation after 1min but activity had waned and was non-
signiﬁcant by 5min. In contrast, the activation of Rho by a positive
control, sphingosine-1-phosphate (S1P) at 1min was still evident
at 5min (data not shown). Figure 3A conﬁrms that IGFBP-3 sig-
niﬁcantly activated Rho after treatment for 1min (p< 0.01). We
showed previously that IGFBP-3 binds to the beta 1 integrin and
that the accentuating effects of IGFBP-3 were reversed when the
beta 1 integrin was blocked (Burrows et al., 2006). In this study we
found that the ability of IGFBP-3 to activateRhowas blocked in the
presence of a beta 1 blocking antibody and a PKA inhibitor with
a tendency for these effects to be reversed (Figures 3B,C). These
data indicated that the involvement of the beta 1 integrin and
PKA occurred upstream of Rho. We have shown previously that
IGFBP-3 dose-dependently increased the activation of MAPK and
inhibiting MAPK with PD98059 blocked the accentuating effects
of IGFBP-3 on apoptotic triggers (Burrows et al., 2006). Figure 3D
shows that the activation of MAPK by IGFBP-3 (p< 0.01) was
reversed in the presence of Y-27632, such that IGFBP-3 then inhib-
ited MAPK phosphorylation (p< 0.05). These data suggest that
MAPK is downstream of Rho kinase and hence of the beta 1
integrin and PKA.
INHIBITING CERAMIDE SYNTHASE REVERSES THE INTRINSIC
PRO-APOPTOTIC EFFECTS OF IGFBP-3
The sphingolipid rheostat describes the dynamic balance that
exists between intracellular S1P and ceramide which have oppos-
ing actions. To investigate whether IGFBP-3 affected this balance
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FIGURE 2 | Photomicrographs of Hs578T cells showing (A)
morphological alteration in the presence ofY-27632 (1, 2, and 5μM).
Cells were captured (magniﬁcation ×100) as described in Section “Materials
and Methods” (B) changes in actin stress ﬁbers and microtubule organization.
Cells were seeded at 0.1× 106 cells per coverslip in GM for 24 h before being
placed into SFM for a further 24 h±Y-27632 (5μM) for 4 h. Cells were stained
and captured (magniﬁcation of ×40) as described in Section “Materials and
Methods.” Hs578T cells were seeded in six-well plates at 0.1× 106 cells in
GM followed by 24 h in SFM prior to pre-dosing with (C) IGFBP-3 (100 ng/ml)
or (D) IGFBP-5±Y-27632 (5μM). The cells were then re-dosed with IGFBP-3
or IGFBP-5 (each at 100 ng/ml) for a further 24 h in the presence or absence of
an apoptotic dose of C2-ceramide. The graphs represent changes in cell death
and show the mean±SEM of three experiments each repeated in
triplicate.
we initially inferred the involvement of ceramide by using an
inhibitor of ceramide synthase, fumonisin B1, which blocks
endogenous production of ceramide. Figures 4A,B show that
the enhancing effects of IGFBP-3 and SPD respectively on C2-
ceramide-induced cell death (p< 0.01 for each) were reversed by
fumonisin B1, such that IGFBP-3 and SPD each acted as a sur-
vival factor (p< 0.05 for each), consistent with an unveiling of
the effect of increased S1P. This reversal was similarly observed
when we used an alternative trigger of apoptosis, antimycin A
(Figure 4C). We found no evidence to suggest that the activation
of Rho by IGFBP-3 was modulated in the presence of fumon-
isin B1 (data not shown) but Figures 5A,B indicate that IGFBP-3
can no longer activate p-MAPK in the presence of fumonisin
B1, suggesting that ceramide is acting upstream of MAPK in the
enhancement of cell death by IGFBP-3, but downstream of Rho.
As anticipated, we show in Figure 5C, that the survival effect of
IGFBP-5 against C2-induced cell death was unaffected by blocking
ceramide production with fumonisin B1.
NEUTRALIZING CELL SURFACE CERAMIDE REVERSES THE INTRINSIC
PRO-APOPTOTIC EFFECTS OF IGFBP-3
We also then measured levels of ceramide on the cell surface
as described previously (Grassme et al., 2001). Figure 6A indi-
cates that neither IGFBP-3 nor the apoptotic trigger antimycin A
alone had any effect, but in combination IGFBP-3 caused a sig-
niﬁcant increase in the levels of ceramide detected on the cell
surface (p< 0.05) We next neutralized surface ceramide using
the ceramide antibody as a blocking antibody in the apoptosis
assay as described previously (Grassme et al., 2001) and show in
Figure 6B that this reversed the accentuating actions of IGFBP-3
on antimycin A (p< 0.001), such that IGFBP-3 conferred survival
(p< 0.05). This would be consistent with a shift in the rheo-
stat and a contemporaneous increase in S1P, the effect of which
was unveiled when the ceramide was blocked. The control IgM
antibody was without effect (data not shown). Figure 6C sup-
ports these results visually with photomicrographs of the cells.
The ceramide antibody and IGFBP-3 alone had no effect on the
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FIGURE 3 | Hs578T were seeded at 0.3× 106 perT25 culture flasks for 24h
after which the GM was replaced with SFM for 24h. Cells were treated
(A) with IGFBP-3 (100ng/ml) for 30min or (B) with IGFBP-3 (100ng/ml)
following a 30-min pre-dose with an anti-beta 1 integrin blocking
antibody (200ng/ml) or (C) a PKA inhibitor KT5720 (1μM). Following
treatment activation of Rho was assessed as described in Section “Materials
and Methods.” (A–C) showWestern immunoblots (of active and total Rho and
are representative of experiments repeated three times) and graphs of the
mean arbitrary optical density measurements from three experiments
demonstrating the change in active Rho compared to the control. (D) Cells
were treated with IGFBP-3 (100 ng/ml) for 30min following a 30-min
pre-dose withY-27632 (5μM) and showsWestern immunoblots of p-MAPK
and total ERK-2 and are representative of experiments repeated three
times. The graph shows the mean arbitrary optical density measurements
from three experiments demonstrating changes in p-MAPK corrected for
ERK-2.
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FIGURE 4 | Hs578T cells were seeded in six-well plates at 0.1× 106 cells
in GM followed by 24h in SFM prior to pre-dosing for 24h (A) with
IGFBP-3 (100ng/ml), (B) SPD (10ng/ml) or (C) IGFBP-3± fumonisin B1
(1μM). Cells were then re-dosed for 24 h± an apoptotic dose of
C2-ceramide (A,B) or antimycin A (C).The graphs represent changes in cell
death and show the mean±SEM of three experiments each repeated in
triplicate.
appearance of the cells relative to the control panel. As antici-
pated with the induction of apoptosis Antimycin A caused cell
detachment with an increase in ﬂoating cells. A number of cells
remaining on the plate exhibited amore rounded appearance. The
cells were unchanged when either IGFBP-3 or antimycin A were
co-incubatedwith the ceramide antibody. The effects of antimycin
A were exacerbated by IGFBP-3, coincident with the ability of
IGFBP-3 to enhance antimycin A-induced cell death. Very few
cells were left attached to the plate and of these a high number
were rounded in appearance. In the presence of the ceramide anti-
body, it is clear that the effects of IGFBP-3 on antimycinA-induced
apoptosis were reversed and that fewer of the cells were rounded
and ﬂoating in comparison to antimycin A alone. We showed
previously that the survival effect of IGFBP-5 was blocked when
we inhibited the production of sphingosine-1-phosphate with a
sphingosine kinase inhibitor,DMS (McCaig et al., 2002c).We then
used the same approach to establish whether the other side of
the sphingolipid rheostat was involved in the effects of IGFBP-3.
Figure 6D indicates that the level of accentuation of cell death by
IGFBP-3 on plastic was actually doubled when sphinogosine-1-
phosphate production was blocked with the sphingosine kinase
inhibitor (p< 0.001). In Figure 1A we showed that PKA was
involved in the accentuating effects of SPD/IGFBP-3 on apoptotic
triggers. Our data imply that the pro-apoptotic effect of IGFBP-3
involved the production of ceramide that was partly counterbal-
anced by increased production of S1P such that when the latter
was blocked then the effect on cell death was enhanced.
DISCUSSION
Integrin receptors congregate in cholesterol-stabilizedmicrodomains
within the plasma membrane that form platforms for the cluster-
ing of cell signaling components (Brown, 2000). Caveolin 1 is a
recognizedmarker of such domains andwe have previously shown
that IGFBP-3 can bind to both caveolin-1 and the beta 1 integrin
and increase their association (Burrows et al., 2006). It has been
reported that IGFBP-3 speciﬁcally binds to the scaffolding domain
of caveolin 1 (CSD; Lee et al., 2004; Singh et al., 2004). This would
require entry of IGFBP-3 into the cell, which has been shown to
occur via both caveolae and clathrin-mediated pathways (Lee et al.,
2004; Singh et al., 2004). One of the main signaling molecules that
is bound and inhibited by the CSD is PKA (Levin et al., 2007).
We have shown that the pro-apoptotic actions of IGFBP-3 were
reversed when the activity of PKA was inhibited. These data sug-
gest that IGFBP-3 may activate PKA by displacing it from the CSD
and the active PKA is involved in the accentuating effects of IGFBP-
3 on apoptotic triggers. We also found that the survival effect of
IGFBP-5 was unaffected in the presence of the PKA inhibitor, in
keeping with our previous work showing the survival effect of
IGFBP-5 was PKC-dependent (McCaig et al., 2002c). Collectively
we suggest that the accentuating effects of IGFBP-3 on apoptotic
triggers are PKA-dependent and reversible, whereas the ability of
IGFBP-5 to confer survival is PKC-dependent and not reversible.
The initiation of integrin signaling requires the clustering of
integrins and the formation of focal contacts. PKA is a key acti-
vator of Rho (Howe, 2004) and the formation of integrin clusters
requires re-modeling of the actin cytoskeleton, which is achieved
primarily through controlled activation of the Rho GTPases
(Ridley and Hall, 1992; Schwartz et al., 1995; Yamada and
Miyamoto, 1995). However Rho GTPase activity is not limited
to cytoskeletal re-arrangement, they are also involved in cell
cycle progression, apoptosis, cytokinesis, and cell transformation
(Ridley, 2001). Rho kinase (ROCK) is a serine/threonine kinase
and a key target for Rho signaling (Bishop and Hall, 2000). By
blocking ROCK we were again able to reverse the accentuating
actions of IGFBP-3, whereas the survival effect of IGFBP-5 was
unaffected. This suggested that the pro-apoptotic effects of IGFBP-
3 required activation of ROCK and again this was reversible. Since
ROCK contributed to the pro-apoptotic actions of IGFBP-3, we
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FIGURE 5 | Hs578T were seeded at 0.3× 106 perT25 culture flasks
for 24h after which the GM was replaced with SFM for 24h. Cells
were treated with IGFBP-3 (100ng/ml) for 30min following a
30-min pre-dose with fumonisin B1 (1μM). (A) ShowsWestern
immunoblots of p-MAPK and ERK-2 and are representative of
experiments repeated three times. (B) Shows a graph of the mean
arbitrary optical density measurements from three experiments
demonstrating changes in p-MAPK corrected for total ERK-2. (C) Hs578T
cells were seeded in six-well plates at 0.1× 106 cells in GM followed
by 24 h in SFM prior to pre-dosing for 24 h with IGFBP-5
(100 ng/ml)± fumonisin B1 (1μM). Cells were then re-dosed for 24 h as
above± an apoptotic dose of C2-ceramide.The graph represents changes in
cell death and shows the mean±SEM of three experiments each repeated in
triplicate.
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FIGURE 6 | Hs578T cells were seeded in six-well plates at 0.1× 106 cells
in GM followed by 24h in SFM. Cells were pre-dosed for 24h with
IGFBP-3 (100ng/ml) prior to redosing± an apoptotic dose of antimycin
A (A). Graph represents cell surface ceramide as assessed by ﬂow
cytometry and is the mean±SEM of three experiments. Cells were
pre-dosed with IGFBP-3 for 24 h± a ceramide blocking antibody (1μg/ml)
prior to redosing± an apoptotic dose of antimycin A (B). Graph represents
changes in cell death and shows the mean±SEM of three experiments
each repeated in triplicate. (C) Shows phase contrast photomicrographs
(magniﬁcation ×100) of Hs578T cells following treatment described in (B),
which are representative of experiments repeated three times. Cells were
pre-dosed for 24 h with IGFBP-3 (100 ng/ml)±DMS (0.5μM) and then
re-dosed± an apoptotic dose of C2-ceramide (D).The graph represents
changes in cell death and shows the mean±SEM of three experiments
each repeated in triplicate.
assessed and conﬁrmed that IGFBP-3 activated its upstream reg-
ulator Rho. As the activation of Rho was inhibited by the PKA
inhibitor,we concluded that PKAwasupstreamof Rho.We showed
previously that blocking the beta 1 integrin receptor reversed the
actions of IGFBP-3 such that it went from promoting to inhibit-
ing triggers of apoptosis. We now conﬁrm that this interaction
is also upstream of Rho, since the beta 1 blocking antibody also
blocked the effects of IGFBP-3 on Rho activation. Cholesterol-
stabilized microdomains are sphingolipid rich and changes in the
relative levels of ceramide and S-1P, which constitute the “sphin-
golipid rheostat,” can determine whether a cell survives or dies. A
shift toward higher intracellular levels of S-1P is associated with
growth and survival, and increased concentrations of ceramide
leads to growth inhibition and/or apoptosis (Cuvillier et al., 1996).
We found that IGFBP-3 was even more effective at accentuating
apoptosis when sphingosine kinase was inhibited, suggesting that
S1P production was opposing the effect of IGFBP-3 to enhance
apoptosis and then when S1P production was inhibited this then
tilted the balance in favor of ceramide generation.
Indeed inhibiting ceramide synthase, which blocks ceramide
production and tilts the balance back in favor of the survival fac-
tor S1P, reversed the accentuating effects of both IGFBP-3 and
SPD, such that they both then acted as survival factors. Since we
originally suggested the involvement of the sphingolipid rheostat
in the intrinsic effects of IGFBP-3 (Perks et al., 2004) there have
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FIGURE 7 | Signaling molecules involved in the pathway by which
IGFBP-3 enhances apoptotic triggers: Inhibition of which can lead to
IGFBP-3 having the opposite effect. IGFBP-3 is able to have either
enhancing or inhibiting effects on apoptotic triggers depending upon the
context.
been reports conﬁrming that at least one side of this balance is
involved in speciﬁc effects of IGFBP-3 on apoptosis (Granata et al.,
2004) and the effects of IGFBP-3 on EGF-induced growth (Martin
et al., 2009).We now provide evidence that IGFBP-3 can affect the
sphingolipid rheostat in both directions and that this provides an
explanation for the different reports of apparently contradicting
actions. It is well established that ceramide can be generated at
numerous sites within a cell (van Blitterswijk et al., 2003) and that
ceramide in the plasma membrane plays an important role as a
membrane structural component being involved in receptor clus-
tering, vesicle formation and fusion (van Blitterswijk et al., 2003).
Ligation of a number of cell surface receptors, including inte-
grin receptors also results in rapid clustering, which is required
for efﬁcient receptor-mediated signaling (Schatzmann et al., 2003;
Bollinger et al., 2005). Extracellularly orientated ceramide has been
shown to play a key part in CD95 clustering that culminated in
apoptosis, which was inhibited when the cell surface ceramide
was neutralized (Grassme et al., 2001). We found that IGFBP-3
alone had no effect on cell surface ceramide, but it did enhance
the levels in the presence of an apoptotic trigger, consistent with
it having no effect on apoptosis alone but being able to enhance
triggers of cell death. Neutralizing the cell surface ceramide caused
IGFBP-3 action to be reversed from enhancing to inhibiting apop-
tosis, as we had observed when we inhibited ceramide synthase
with fumonisin B1. These data indicate that cell surface ceramide
contributes to the way in which IGFBP-3 modulates apoptosis,
but does not preclude that intracellular ceramide might also play
a part. Together our ﬁndings suggest that alterations in the spe-
ciﬁc spatial organization of integrin receptors, sphingolipids, and
signaling molecules within cholesterol-stabilized complexes may
modify the response of the cells to IGFBP-3. We found no evi-
dence to suggest that fumonisin B1 affected the ability of IGFBP-3
to activate Rho, suggesting that the involvement of ceramide is
downstream of Rho.
We have shown previously that the accentuating effects of
IGFBP-3 on apoptotic triggers involving cholesterol-stabilized
integrin receptor complexes culminated in the activation ofMAPK
(Burrows et al., 2006). We now show that the activation of MAPK
is blocked in the presence of fumonisin B1, which suggests that
MAPK is downstream of the beta 1 integrin, PKA, Rho, and
ceramide in the pathwaywhich IGFBP-3uses to accentuate triggers
of apoptosis.
We established previously that IGFBP-3 could exert positive
or negative effects on cell function depending upon the extracel-
lular matrix composition (McCaig et al., 2002b; Burrows et al.,
2006). We also showed that IGFBP-3 was able to modulate down-
stream signaling events initiated by integrins through enhanced
phosphorylation of MAPK (Burrows et al., 2006). However,
although the actions of IGFBP-3 could be reversed by disrupting
integrin receptor complexes (Burrows et al., 2006), they were not
reversible whenMAPKwas inhibited; the actions of IGFBP-3 were
just blocked. In this study we have identiﬁed key components
of cholesterol-stabilized integrin receptor signaling, PKA, Rho,
and ceramide, which are involved in the intrinsic, pro-apoptotic
actions of IGFBP-3. Furthermore, we determined that they are
upstream of MAPK and when each are blocked, the actions of
IGFBP-3 are reversed (see Figure 7). It has been proposed that
IGFBP-3 could be used therapeutically to treat cancers due to its
ability to inhibit growth and promote apoptosis. These data high-
light the importance of understanding the mechanism by which
IGFBP-3 actions can be reversed from a negative to a positive reg-
ulator, since attempting to inhibit or promote IGFBP-3 function
could actually lead to it having the opposite effect.
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